Literature DB >> 2848722

Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung.

S M Kanse1, B Kreymann, M A Ghatei, S R Bloom.   

Abstract

High-affinity binding sites for glucagon-like peptide-1 7-36 amide (GLP-1 7-36 NH2) were identified in rat brain and lung membranes. Binding of [125I]GLP-1 7-36 NH2 was rapid, reversible, specific, saturable and pH dependent. Specific binding in the central nervous system was particularly high in the hypothalamus and the brain stem. Oxyntomodulin, glucagon-like peptide-1, glucagon-like peptide-2 and glucagon were 100-1000-fold less potent than GLP-1 7-36 NH2 in competition for this binding site.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848722     DOI: 10.1016/0014-5793(88)81063-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

Review 1.  Promising new approaches to the management of obesity.

Authors:  I L Mertens; L F Van Gaal
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 3.  The gut and food intake: an update for surgeons.

Authors:  E Näslund; P M Hellström; J G Kral
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

Review 4.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

Review 5.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

Authors:  K Pabreja; M A Mohd; C Koole; D Wootten; S G B Furness
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

6.  Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

Authors:  C Qualmann; M A Nauck; J J Holst; C Orskov; W Creutzfeldt
Journal:  Acta Diabetol       Date:  1995-03       Impact factor: 4.280

Review 7.  Glucagon-like peptide 1 and appetite.

Authors:  Megan J Dailey; Timothy H Moran
Journal:  Trends Endocrinol Metab       Date:  2013-01-16       Impact factor: 12.015

Review 8.  Glucagon-like peptide-1, a new hormone of the entero-insular axis.

Authors:  C Orskov
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

9.  Glucagon-like peptide-1 is a physiological incretin in rat.

Authors:  Z Wang; R M Wang; A A Owji; D M Smith; M A Ghatei; S R Bloom
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions.

Authors:  Gregory M Holmes; Kirsteen N Browning; Melissa Tong; Emily Qualls-Creekmore; R Alberto Travagli
Journal:  J Physiol       Date:  2009-08-12       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.